ENHERTU Demonstrated Statistically Significant and Clinically Meaningful OS Improvement in Patients with HER2+ve Metastatic Gastric Cancer at Interim Analysis of DESTINYGastric04 Ph 3 Trial March 11, 2025
Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced March 11, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
Positive Topline Ph 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Grade 1/2 SSTR+ve GEP-NETs Presented March 11, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
Camizestrant demonstrated highly statistically significant improvement in PFS in 1L advanced HR+ve breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Ph 3 trial March 4, 2025
GEMSTONE-303 article published in JAMA, highlighting efficacy of sugemalimab + CAPOX vs placebo + CAPOX as 1L treatment for patients with unresectable locally advanced/metastatic G/GEJ adenocarcinoma with PD-L1 CPS ≥5 March 4, 2025
Additional Positive Data from Ph 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors Presented March 4, 2025
Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology March 4, 2025
Neoadjuvant Opdivo® + Chemo Demonstrate Statistically Significant and Clinically Meaningful OS in Resectable NSCLC February 25, 2025
Translational Data Announced from Ph 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 25, 2025
FAILED TRIAL: Ph 3 RELATIVITY-098 trial of Opdualag™ (nivolumab and relatlimab-rmbw) in adjuvant, stage III-IV melanoma did not meet its primary endpoint of RFS February 19, 2025
ASCO GU 2025: PADCEV + KEYTRUDA Show Long-Term Efficacy in 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer February 19, 2025
IMFINZI perioperative regimen improved EFS and OS across MIBC patients regardless of cPR status in post-hoc exploratory analysis of NIAGARA Ph 3 trial February 19, 2025
Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with R/R MZL Announced February 19, 2025
Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in Ph 1/2 TUSCANY Trial February 19, 2025
Data from Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median DOR of ~4 Years in Patients Achieving CR with JELMYTO Published in The Journal of Urology February 19, 2025
ASCO GU 2025: Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX + Opdivo in Patients with Advanced Kidney Cancer Announced February 19, 2025
ASCO GU 2025: New Data reported for Casdatifan in Patients with Metastatic Kidney Cancer February 19, 2025
ASCO GU 2025: New data for darolutamide confirm safety and improved efficacy across subgroups of patients with mHSPC February 19, 2025
